Thymus radiation exposure linked to worse lung cancer outcomes in new study

For decades, doctors treated the thymus as a relic—an organ that mattered in childhood and then faded into irrelevance. It sits in the upper chest, a small gland responsible for producing and training T cells, those immune sentries that recognize infections and fight cancer. By adulthood, it shrinks, its functional tissue replaced by fat, and the medical establishment largely forgot about it. But a new study published in Annals of Oncology suggests that forgetting the thymus may have cost lung cancer patients their lives.

Researchers analyzed 1,107 patients with non-small cell lung cancer and found something unexpected: patients whose thymus received radiation during cancer treatment had significantly worse outcomes. The cancer was more likely to spread to distant parts of the body, and patients were more likely to die. The catch was important—this effect appeared only in patients whose thymus was still relatively healthy before treatment began. Those were the patients who should have had the best prognosis overall. Instead, they became the most vulnerable to an unintended consequence of their own therapy.

The work builds on earlier research by the same team at Harvard and Mass General Brigham that challenged the old assumption about the adult thymus. Recent studies published in Nature found that while adults produce fewer new T cells than children do, some people retain substantially more functional thymic tissue than others. That variation matters. People with healthier thymic tissue showed greater T-cell diversity, lived longer, developed less cancer, and responded better to immunotherapy. The thymus, it turned out, was not irrelevant at all.

For this study, researchers used artificial intelligence to examine routine CT scans from three separate patient groups. They scored the health of each patient's thymus by analyzing its size, shape, density, and tissue composition before radiotherapy began. They also calculated how much radiation each thymus actually received during treatment—a dose that was never intended, since the thymus is not the target of lung cancer therapy. But because it sits in the middle of the chest, it often gets caught in the crossfire.

The numbers were stark. Among patients with healthy thymic tissue before treatment, those who received higher radiation doses to the thymus faced a 29 percent higher risk of distant metastasis in one clinical trial, 33 percent higher in another cohort, and 95 percent higher in patients who also received the immunotherapy drug durvalumab. One year after treatment, patients who received higher thymic radiation showed measurable loss of thymic health and, in some cases, lower lymphocyte counts—suggesting the radiation had directly damaged the immune organ.

What made the finding potentially transformative was what the researchers did not find: they did not find that protecting the thymus would require new technology or new treatments. Using existing radiotherapy planning techniques, radiation oncologists could often substantially reduce thymic exposure without compromising cancer control or increasing radiation to other vital organs like the heart or lungs. The tools already exist. The knowledge did not.

Hugo Aerts, the senior author and director of the Artificial Intelligence in Medicine program at Mass General Brigham, framed the finding as part of a larger shift in how medicine might approach treatment. "Modern oncology increasingly depends on the patient's immune system, particularly as immunotherapies become part of standard treatment," he said. The thymus could become one of the first immune organs routinely protected during treatment planning—not as an afterthought, but as a deliberate principle of care.

The study has limitations. The patients were predominantly white, and the findings need validation in more diverse populations. The AI models used to assess thymic health require further testing across different scanners and institutions. The researchers themselves note that the radiation dose threshold they used was exploratory, not yet a validated clinical standard. But the consistency of the finding across three separate patient groups—treated over two decades, with different protocols and different outcomes—suggests something real.

The next step is prospective studies to confirm that protecting the thymus actually improves survival. If they do, the change could come relatively quickly. Unlike many medical advances, this one does not require inventing new tools. It requires only that radiation oncologists begin to think of the thymus the way they already think of the heart and lungs—as an organ worth protecting, even when it is not the obvious target of treatment.